WSWisoo Shin

Wisoo Shin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wisoo Shin has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Malnutrition in Older Adults With Chronic Wounds: A Prospective Cohort Study

    by Wisoo Shin, Maria Weatherbee, Zahra Rehan, Eileen Emmott, Laurie Parsons

    OBJECTIVE: To determine the prevalence of malnutrition among older adults with chronic wounds. METHODS: A prospective cohort study was conducted to assess the nutrition status of adults over the age of 65 with a chronic wound. Participants who met inclusion criteria were recruited at the Sheldon Chumir Wound Clinic in Calgary, Alberta, Canada, from April 1, 2022, to March 31, 2023. The primary outcome was the diagnosis of malnutrition. Secondary outcomes included other nutrition diagnoses and identified diet barriers. Patient demographic and characteristic information were also collected. RESULTS: A total of 78 patients were included in the study, with a mean age of 75.9±7.7 years. A clinical diagnosis of malnutrition was made in 24.4% of participants, with more than two-thirds of the participants diagnosed with inadequate protein intake (69.2%) and knowledge deficiency (67.9%). Common dietary barriers included loss of appetite (46.2%), eating meals alone (30.2%), and constipation (19.2%). Older age increased the odds of malnutrition (odds ratio, 1.20; P =.004). In contrast, being male was associated with a lower likelihood of malnutrition (odds ratio, 0.07; P =.030). Patients with a psychiatric diagnosis had markedly higher odds of malnutrition (odds ratio, 76.89; P =.006), as did those with hypothyroidism (odds ratio, 20.55; P =.046). CONCLUSIONS: Previously, 34.2% of community-dwelling older adults in Canada were estimated to be at risk of malnutrition. The present study clinically diagnosed malnutrition in 24.4% of older adults with chronic wounds. This finding reinforces the importance of malnutrition screening in multidisciplinary wound clinics and advocates for establishing nutrition assessments as standard of care for geriatric patients with chronic wounds.

  • Open Access

    Case report: Remission of recalcitrant psoriasis and severe hidradenitis suppurativa following allogeneic hematopoietic stem cell transplantation for GATA2 deficiency

    by Wisoo Shin, George Song-Zhao, Steven M. Holland, Dennis D. Hickstein, P. Régine Mydlarski

    GATA binding protein 2 (GATA2) deficiency is an autosomal dominant immunodeficiency disorder with a broad range of dermatologic manifestations. While psoriasis has recently been linked to GATA2 deficiency, an association with hidradenitis suppurativa (HS) has not been previously reported. We present a case of complete remission of severe psoriasis and Hurley stage III HS following allogeneic hematopoietic stem cell transplantation (HSCT), with remission sustained for at least eight years of follow-up. To our knowledge, this is the first reported case demonstrating sustained remission of both psoriasis and HS following HSCT for GATA2 deficiency. This case strengthens the reported association between psoriasis and GATA2 deficiency and suggests HS as a potential novel cutaneous manifestation.

  • Open Access

    Drop‐In Wound Care: Calgary's Wound Care Model Centred Around People Experiencing Homelessness

    by Wisoo Shin, Mustafa Dahchi, Jennifer Laird, Rinna Lamano, Kelly D. Sair, Eileen Emmott, Laurie Parsons

    People experiencing housing insecurities or homelessness face significant barriers to equitable healthcare. A drop‐in wound care service was established to mitigate social barriers and improve accessibility. This model facilitates direct access to a multidisciplinary team of trauma‐informed medical staff on a walk‐in basis. A retrospective chart review was performed on patients seen at the drop‐in clinic from January 2021 to December 2021. A total of 119 patients were serviced over 798 visits, with 254 unique wounds managed. 82.8% of patients were living unsheltered, in emergency shelters or in provisional accommodation at the time of assessment. Trauma wounds, lower leg ulcers and frostbites represented the top three complaints. 69.7% of all patients returned to service for at least a second visit, with a median of 4 visits per patient over 42.5 days. Unsheltered patients were most likely to return to service (87.5%) but were most likely to be lost prior to wound closure (68.8%). Timely access to care with consistent follow‐up is essential for quality wound care. Our drop‐in service presents a working model for providing equitable wound care to socially disadvantaged patient populations. The effectiveness of this model is highlighted by the continual expansion serving 909 and 1029 visits in subsequent years.

  • Interventions for postburn pruritus

    by Sarthak Sinha, Vincent A Gabriel, Rohit K Arora, Wisoo Shin, Janis Scott, Shyla K Bharadia, Myriam Verly, Waleed M Rahmani, Duncan A Nickerson, Frankie Og Fraulin, et al.

    Background Postburn pruritus (itch) is a common and distressing symptom experienced on healing or healed burn or donor site wounds. Topical, systemic, and physical treatments are available to control postburn pruritus; however, it remains unclear how effective these are. Objectives To assess the effects of interventions for treating postburn pruritus in any care setting. Search methods In September 2022, we searched the Cochrane Wounds Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE (including In‐Process & Other Non‐Indexed Citations), Ovid Embase, and EBSCO CINAHL Plus. We also searched clinical trials registries and scanned references of relevant publications to identify eligible trials. There were no restrictions with respect to language, publication date, or study setting. Selection criteria Randomised controlled trials (RCTs) that enrolled people with postburn pruritus to compare an intervention for postburn pruritus with any other intervention, placebo or sham intervention, or no intervention. Data collection and analysis We used the standard methodological procedures expected by Cochrane. We used GRADE to assess the certainty of the evidence. Main results We included 25 RCTs assessing 21 interventions with 1166 randomised participants. These 21 interventions can be grouped into six categories: neuromodulatory agents (such as doxepin, gabapentin, pregabalin, ondansetron), topical therapies (such as CQ‐01 hydrogel, silicone gel, enalapril ointment, Provase moisturiser, beeswax and herbal oil cream), physical modalities (such as massage therapy, therapeutic touch, extracorporeal shock wave therapy, enhanced education about silicone gel sheeting), laser scar revision (pulsed dye laser, pulsed high‐intensity laser, fractional CO2 laser), electrical stimulation (transcutaneous electrical nerve stimulation, transcranial direct current stimulation), and other therapies (cetirizine/cimetidine combination, lemon balm tea). Most RCTs were conducted at academic hospitals and were at a high risk of performance, attrition, and detection bias. While 24 out of 25 included studies reported change in burn‐related pruritus, secondary outcomes such as cost‐effectiveness, pain, patient perception, wound healing, and participant health‐related quality of life were not reported or were reported incompletely. Neuromodulatory agents versus antihistamines or placebo There is low‐certainty evidence that doxepin cream may reduce burn‐related pruritus compared with oral antihistamine (mean difference (MD) ‐2.60 on a 0 to 10 visual analogue scale (VAS), 95% confidence interval (CI) ‐3.79 to ‐1.42; 2 studies, 49 participants). A change of 2 points represents a minimal clinically important difference (MCID). Due to very low‐certainty evidence, it is uncertain whether doxepin cream impacts the incidence of somnolence as an adverse event compared to oral antihistamine (risk ratio (RR) 0.64, 95% CI 0.32 to 1.25; 1 study, 24 participants). No data were reported on pain in the included study. There is low‐certainty evidence that gabapentin may reduce burn‐related pruritus compared with cetirizine (MD ‐2.40 VAS, 95% CI ‐4.14 to ‐0.66; 1 study, 40 participants). A change of 2 points represents a MCID. There is low‐certainty evidence that gabapentin reduces the incidence of somnolence compared to cetirizine (RR 0.02, 95% CI 0.00 to 0.38; 1 study, 40 participants). No data were reported on pain in the included study. There is low‐certainty evidence that pregabalin may result in a reduction in burn‐related pruritus intensity compared with cetirizine with pheniramine maleate (MD ‐0.80 VAS, 95% CI ‐1.24 to ‐0.36; 1 study, 40 participants). A change of 2 points represents a MCID. There is low‐certainty evidence that pregabalin reduces the incidence of somnolence compared to cetirizine (RR 0.04, 95% CI 0.00 to 0.69; 1 study, 40 participants). No data were reported on pain in the included study. There is moderate‐certainty evidence that ondansetron probably results in a reduction in burn‐related pruritus intensity compared with diphenhydramine (MD ‐0.76 on a 0 to 10 numeric analogue scale (NAS), 95% CI ‐1.50 to ‐0.02; 1 study, 38 participants). A change of 2 points represents a MCID. No data were reported on pain and adverse events in the included study. Topical therapies versus relevant comparators There is moderate‐certainty evidence that enalapril ointment probably decreases mean burn‐related pruritus compared with placebo control (MD ‐0.70 on a 0 to 4 scoring table for itching, 95% CI ‐1.04 to ‐0.36; 1 study, 60 participants). No data were reported on pain and adverse events in the included study. Physical modalities versus relevant comparators Compared with standard care, there is low‐certainty evidence that massage may reduce burn‐related pruritus (standardised mean difference (SMD) ‐0.86, 95% CI ‐1.45 to ‐0.27; 2 studies, 166 participants) and pain (SMD ‐1.32, 95% CI ‐1.66 to ‐0.98). These SMDs equate to a 4.60‐point reduction in pruritus and a 3.74‐point reduction in pain on a 10‐point VAS. A change of 2 VAS points in itch represents a MCID. No data were reported on adverse events in the included studies. There is low‐certainty evidence that extracorporeal shock wave therapy (ESWT) may reduce burn‐related pruritus compared with sham stimulation (SMD ‐1.20, 95% CI ‐1.65 to ‐0.75; 2 studies, 91 participants). This equates to a 5.93‐point reduction in pruritus on a 22‐point 12‐item Pruritus Severity Scale. There is low‐certainty evidence that ESWT may reduce pain compared with sham stimulation (MD 2.96 on a 0 to 25 pressure pain threshold (PPT),...


  • Open Access

    Loss of Ubiquitin Carboxy-Terminal Hydrolase L1 Impairs Long-Term Differentiation Competence and Metabolic Regulation in Murine Spermatogonial Stem Cells

    by Whitney F. Alpaugh, Anna L. Voigt, Rkia Dardari, Lin Su, Iman Al Khatib, Wisoo Shin, Taylor M. Goldsmith, Krysta M. Coyle, Lin A. Tang, Timothy E. Shutt, et al.

    Spermatogonia are stem and progenitor cells responsible for maintaining mammalian spermatogenesis. Preserving the balance between self-renewal of spermatogonial stem cells (SSCs) and differentiation is critical for spermatogenesis and fertility. Ubiquitin carboxy-terminal hydrolase-L1 (UCH-L1) is highly expressed in spermatogonia of many species; however, its functional role has not been identified. Here, we aimed to understand the role of UCH-L1 in murine spermatogonia using a Uch-l1−/− mouse model. We confirmed that UCH-L1 is expressed in undifferentiated and early-differentiating spermatogonia in the post-natal mammalian testis. The Uch-l1−/− mice showed reduced testis weight and progressive degeneration of seminiferous tubules. Single-cell transcriptome analysis detected a dysregulated metabolic profile in spermatogonia of Uch-l1−/− compared to wild-type mice. Furthermore, cultured Uch-l1−/− SSCs had decreased capacity in regenerating full spermatogenesis after transplantation in vivo and accelerated oxidative phosphorylation (OXPHOS) during maintenance in vitro. Together, these results indicate that the absence of UCH-L1 impacts the maintenance of SSC homeostasis and metabolism and impacts the differentiation competence. Metabolic perturbations associated with loss of UCH-L1 appear to underlie a reduced capacity for supporting spermatogenesis and fertility with age. This work is one step further in understanding the complex regulatory circuits underlying SSC function.


  • Open Access

    Transcriptional Profiling of the Adult Hair Follicle Mesenchyme Reveals R-spondin as a Novel Regulator of Dermal Progenitor Function

    by Andrew Hagner, Wisoo Shin, Sarthak Sinha, Whitney Alpaugh, Matthew Workentine, Sepideh Abbasi, Waleed Rahmani, Natacha Agabalyan, Nilesh Sharma, Holly Sparks, et al.


  • Burn clinical trials: A systematic review of registration and publications

    by Sarthak Sinha, Grace Yoon, Wisoo Shin, Jeff A. Biernaskie, Duncan Nickerson, Vincent A. Gabriel